Shrigun Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 25-06-2024
- Paid Up Capital ₹ 1.00 Cr
as on 25-06-2024
- Company Age 24 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.80 Cr
as on 25-06-2024
- Satisfied Charges ₹ 13.60 Cr
as on 25-06-2024
- Revenue 6.23%
(FY 2023)
- Profit 105.34%
(FY 2023)
- Ebitda -30.82%
(FY 2023)
- Net Worth 1.45%
(FY 2023)
- Total Assets 12.76%
(FY 2023)
About Shrigun Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹6.80 Cr. The company has closed loans amounting to ₹13.60 Cr, as per Ministry of Corporate Affairs (MCA) records.
Meghana Doshi, Shrikant Doshi, and Gunvant Doshi serve as directors at the Company.
- CIN/LLPIN
U52311MH2000PTC126802
- Company No.
126802
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shrigun Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meghana Doshi  | Director | 07-Jun-2005 | Current |
| Shrikant Doshi | Director | 29-May-2000 | Current |
| Gunvant Doshi | Director | 01-Jul-2000 | Current |
Financial Performance of Shrigun Pharmachem.
Shrigun Pharmachem Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.23% increase. The company also saw a substantial improvement in profitability, with a 105.34% increase in profit. The company's net worth moved up by a moderate rise of 1.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shrigun Pharmachem?
In 2023, Shrigun Pharmachem had a promoter holding of 88.30% and a public holding of 11.70%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Doshi Medical Service Private LimitedActive 11 years 8 monthsMeghana Doshi, Shrikant Doshi and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 02 Feb 2010 | ₹2.00 M | Open |
Bank Of India Creation Date: 01 Feb 2010 | ₹2.10 Cr | Open |
Bank Of India Creation Date: 01 Feb 2010 | ₹1.80 Cr | Open |
How Many Employees Work at Shrigun Pharmachem?
Unlock and access historical data on people associated with Shrigun Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shrigun Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shrigun Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
